This week in charts: Moderna’s massive stock run
Start here
Moderna shares have risen more than 600% in 2026, far outpacing the XBI biotech index fund's 23% gain, after the Phase 3 success in August of intismeran autogene, a melanoma vaccine co-developed with Merck. Analysts say detailed results due at a medical meeting later this month will shape whether the run continues. Separately, Roche has struck five deals with Chinese drugmakers since late August, collectively worth more than $5 billion, spanning obesity candidates and molecular glue drugs.
Excerpted from biopharmadive.com
Coverage timeline
Follow the coverage to see the different angles.
- biopharmadive.comPickThis week in charts: Moderna’s massive stock run
Moderna shares have risen more than 600% in 2026, far outpacing the XBI biotech index fund's 23% gain, after the Phase 3 success in August of intismeran autogene, a melanoma vaccine co-developed with Merck. Analysts say detailed results due at a medical meeting later this month will shape whether the run continues. Separately, Roche has struck five deals with Chinese drugmakers since late August, collectively worth more than $5 billion, spanning obesity candidates and molecular glue drugs.
Heat trend for this story
Heat now 9·Peak in the comparable set 10 (Oct 16 23:00)·Change over 24h in the comparable set –
The trend compares only the participants observed in full throughout, so its set can be smaller than the heat figure itself. Move the pointer or click the chart for an hour's heat; the left and right arrow keys work too.